1
|
Soldati E, Escoffier L, Gabriel S, Ogier AC, Chagnaud C, Mattei JP, Cammilleri S, Bendahan D, Guis S. Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient. PLoS One 2021; 16:e0251788. [PMID: 34010320 PMCID: PMC8133422 DOI: 10.1371/journal.pone.0251788] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 05/04/2021] [Indexed: 01/22/2023] Open
Abstract
Objective Psoriatic arthritis (PsA) is an inflammatory rheumatic disease, mediated in part by TNFα and associated with bone loss. Anti-TNFα treatment should inhibit this phenomenon and reduce the systemic bone loss. Ultra-high field MRI (UHF MRI) may be used to quantify bone microarchitecture (BM) in-vivo. In this study, we quantified BM using UHF MRI in a PsA patient and followed up the changes related to anti-TNFα treatment. Subjects and methods A non-treated PsA patient with knee arthritis and 7 gender-matched controls were scanned using a gradient re-echo sequence at UHF MRI. After a year of Adalimumab treatment, the patient underwent a second UHF MRI. A PET-FNa imaging was performed before and after treatment to identify and localize the abnormal metabolic areas. BM was characterized using typical morphological parameters quantified in 32 regions of interest (ROIs) located in the patella, proximal tibia, and distal femur. Results Before treatment, the BM parameters were statistically different from controls in 24/32 ROIs with differences reaching up to 38%. After treatment, BM parameters were normalized for 15 out of 24 ROIs. The hypermetabolic areas disclosed by PET-FNa before the treatment partly resumed after the treatment. Conclusion Thanks to UHF MRI, we quantified in vivo BM anomalies in a PsA patient and we illustrated a major reversion after one year of treatment. Moreover, BM results highlighted that the abnormalities were not only localized in hypermetabolic regions identified by PET-FNa, suggesting that the bone loss was global and not related to inflammation.
Collapse
Affiliation(s)
- Enrico Soldati
- Aix-Marseille Université, CNRS, CRMBM-CEMEREM, Marseille, France.,Aix-Marseille Université, CNRS, IUSTI, Marseille, France.,Aix-Marseille Université, CNRS, ISM, Marseille, France
| | - Lucas Escoffier
- Aix-Marseille Université, Service de Rhumatologie, AP-HM, Marseille, France
| | - Sophie Gabriel
- Aix-Marseille Université, Service de Médecine Nucléaire, AP-HM, Institut Fresnel, Marseille, France
| | - Augustin C Ogier
- Aix-Marseille Université, CNRS, CRMBM-CEMEREM, Marseille, France.,Aix-Marseille Université, Université de Toulon, CNRS, LIS, Marseille, France
| | | | - Jean P Mattei
- Aix-Marseille Université, CNRS, CRMBM-CEMEREM, Marseille, France.,Aix-Marseille Université, Service de Rhumatologie, AP-HM, Marseille, France
| | - Serge Cammilleri
- Aix-Marseille Université, Service de Médecine Nucléaire, AP-HM, Institut Fresnel, Marseille, France
| | - David Bendahan
- Aix-Marseille Université, CNRS, CRMBM-CEMEREM, Marseille, France
| | - Sandrine Guis
- Aix-Marseille Université, CNRS, CRMBM-CEMEREM, Marseille, France.,Aix-Marseille Université, Service de Rhumatologie, AP-HM, Marseille, France
| |
Collapse
|
2
|
Lee M, Yeum TS, Kim JW, Oh S, Lee SA, Moon HR, Choi YH, Han YM, Choi JM, Jang DK. Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer. Gut Liver 2014; 8:254-64. [PMID: 24827621 PMCID: PMC4026642 DOI: 10.5009/gnl.2014.8.3.254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND/AIMS The aim of this study was to evaluate the influence of recent chemotherapy on the patterns of the maximum-standardized uptake value (M-SUV) and sensitivity of (18)F-fluoro-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in colorectal cancer. METHODS We retrospectively analyzed the FDG-PET/CT of 509 patients who underwent surgery for colorectal cancer. Subgroup analysis was performed according to chemotherapy status; 401 patients were not treated with chemotherapy and 108 patients were treated with chemotherapy within 6 months prior to surgery. Pathologic analysis of the surgical specimen was used as the gold standard. RESULTS The M-SUV was significantly lower in patients treated with chemotherapy than in those not treated with chemotherapy in pathologically confirmed same stages of disease. The difference in the sensitivity of the M-SUV according to chemotherapy status was greatest using a cutoff M-SUV value of 6.4 (p<0.001). The longest diameter of the primary tumor was the most important factor that correlated with M-SUV of the primary tumor irrespective of the chemotherapy effect (p<0.001). The M-SUV of the primary tumor was not an independent predictor of lymph node metastasis in colorectal cancer. CONCLUSIONS The results indicate that the M-SUV of FDG-PET/CT should be interpreted in the context of concurrent chemotherapy.
Collapse
Affiliation(s)
- Minjong Lee
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Tae Sung Yeum
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Ji Won Kim
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea, Departments of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Sohee Oh
- Departments of Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
| | - Shin Ae Lee
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Hong Ran Moon
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Young Hoon Choi
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Yoo Min Han
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Ji Min Choi
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| | - Dong Kee Jang
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea
| |
Collapse
|
3
|
Abi-Jaoudeh N, Mielekamp P, Noordhoek N, Venkatesan AM, Millo C, Radaelli A, Carelsen B, Wood BJ. Cone-beam computed tomography fusion and navigation for real-time positron emission tomography-guided biopsies and ablations: a feasibility study. J Vasc Interv Radiol 2012; 23:737-43. [PMID: 22494658 DOI: 10.1016/j.jvir.2012.02.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Revised: 02/09/2012] [Accepted: 02/15/2012] [Indexed: 01/07/2023] Open
Abstract
PURPOSE To describe a novel technique for multimodality positron emission tomography (PET) fusion-guided interventions that combines cone-beam computed tomography (CT) with PET/CT before the procedure. MATERIALS AND METHODS Subjects were selected among patients scheduled for a biopsy or ablation procedure. The lesions were not visible with conventional imaging methods or did not have uniform uptake on PET. Clinical success was defined by adequate histopathologic specimens for molecular profiling or diagnosis and by lack of enhancement on follow-up imaging for ablation procedures. Time to target (time elapsed between the completion of the initial cone-beam CT scan and first tissue sample or treatment), total procedure time (time from the moment the patient was on the table until the patient was off the table), and number of times the needle was repositioned were recorded. RESULTS Seven patients underwent eight procedures (two ablations and six biopsies). Registration and procedures were completed successfully in all cases. Clinical success was achieved in all biopsy procedures and in one of the two ablation procedures. The needle was repositioned once in one biopsy procedure only. On average, the time to target was 38 minutes (range 13-54 min). Total procedure time was 95 minutes (range 51-240 min, which includes composite ablation). On average, fluoroscopy time was 2.5 minutes (range 1.3-6.2 min). CONCLUSIONS An integrated cone-beam CT software platform can enable PET-guided biopsies and ablation procedures without the need for additional specialized hardware.
Collapse
Affiliation(s)
- Nadine Abi-Jaoudeh
- Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda MD 20892, USA.
| | | | | | | | | | | | | | | |
Collapse
|